A recent survey by Ferring Pharmaceuticals has brought to light the extensive struggles couples in Asia face on their fertility journey. The survey, covering seven Asian markets including India, highlights the long and emotional path to conception, often compounded by a lack of knowledge and emotional support. Long Journey to Parenthood The average duration from the decision to conceive to successful conception…
A recent landmark study announced by Eli Lilly and Company has shown significant long-term benefits of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC). The findings, unveiled at the 2023 European Society for Medical Oncology (ESMO) Congress, are particularly significant for those at heightened risk of cancer recurrence. The study focused on hormone receptor-positive, HER2-negative, node-positive early breast cancer. Over five…
Health Canada has granted approval to MYFEMBREE for the management of pain related to endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The drug, a joint venture between Sumitomo Pharma Canada and Pfizer Canada, is an oral combination therapy meant to be taken once daily. Endometriosis and uterine fibroids are serious health issues affecting a significant portion of…
The American Society for Reproductive Medicine (ASRM) and Ferring Pharmaceuticals have announced a $5M endowment from Ferring to ASRM. This endowment, the largest in ASRM’s nearly 80-year history, will establish the “Ferring Endowment for the Education of Healthcare Professionals in Training,” ensuring ASRM’s continued legacy as the leading educator for professionals in the field. ASRM will utilize this endowment to create, establish, and maintain innovative educational programs for healthcare…
Women’s and Men’s Reproductive Health Pharma Company Besins Healthcare, has opened a new hormone production facility in Muel, Spain, bolsteing their global hormone production capacity by a 30%. This milestone is a response to the growing worldwide demand for hormones, particularly concerning late pregnancies and menopause. The opening follows Besins Healthcare’s strategic acquisition of a hormone production site in Drogenbos, Belgium, in…
In a stride forward for women’s health and cervical cancer prevention, Asieris Pharmaceuticals has declared the successful completion of its Phase III clinical trial for APL-1702 (Cevira), a non-surgical treatment aimed at cervical high-grade squamous intraepithelial lesions (HSIL). This significant milestone could shift the paradigm in treating this precancerous condition, offering a less invasive alternative to surgery, and may particularly benefit women…
In an advancement that could change the landscape of endometriosis treatment, pharmaceutical giants Gedeon Richter and Sumitomo Pharma recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for RYEQO. The drug, initially approved for the treatment of uterine fibroids, is on track to receive European Commission (EC) approval for the…
Palatin Technologies has announced a partnership with telehealth service provider UpScriptHealth. The collaboration aims to raise awareness about hypoactive sexual desire disorder (HSDD) and increase the accessibility of Vyleesi through UpScriptHealth’s Women’s Health Platform. According to the company Vyleesi is the only FDA-approved, as-needed treatment for acquired, generalized HSDD in premenopausal women. The partnership will make Vyleesi available to UpScriptHealth’s extensive patient…
